To evaluate the relationship between dynamic changes in the modified Glasgow Prognostic Scale (mGPS) and post-nephrectomy survival among localized clear cell renal cell carcinoma (ccRCC) patients.
We retrospectively identified patients who underwent nephrectomy for localized ccRCC with preoperative mGPS = 0 from 2005 to 2018. The primary exposure of interest was ΔmGPS between two points: 60 days prior to surgery and 1 year after surgery. We assessed the relationship between ΔmGPS and survival outcomes. Kaplan-Meier curves were generated to determine survival estimates and Cox proportional hazards models were fit to estimate hazard ratios. Multivariable models were constructed using both ΔmGPS and clinical variables known to be associated with differences in survival.
We identified 313 patients for our analytic cohort with a median follow-up time of 20.2 months. 37 (11.9%) patients died and 39 (12.54%) showed recurrence during follow-up. 263 (84.6%) patients had unchanged mGPS before and after surgery, while 48 (15.4%) patients showed an increase in postoperative mGPS from preoperative mGPS. Compared to patients with unchanged mGPS, patients with a higher postoperative mGPS had an increased risk of death (HR: 3.05 (1.39-6.68), p=0.005) and recurrence (HR: 2.98 (1.34-6.64), p = 0.008).
Patients with an increase in mGPS following nephrectomy for ccRCC were more likely to die and experience cancer recurrence. Assessing dynamic changes in this cheap, validated, and reproducible test may be useful in identifying patients at higher risk for more aggressive disease or for counseling patients regarding risk of cancer recurrence.
Urology. 2020 Apr 12 [Epub ahead of print]
Dattatraya Patil, Thien-Linh Le, Kc Biebighauser Bens, Mehrdad Alemozaffar, Aaron Lay, John Pattaras, Christopher P Filson, Kenneth Ogan, Mehmet A Bilen, Viraj A Master
Emory University Department of Urology., Emory University Department of Urology; Winship Cancer Institute of Emory University., Winship Cancer Institute of Emory University; Emory University Department of Hematology and Oncology., Emory University Department of Urology; Winship Cancer Institute of Emory University; Emory University Department of Hematology and Oncology. Electronic address: .